跳至主要内容
临床试验/JPRN-jRCT1080222785
JPRN-jRCT1080222785已完成3 期

An exploratory study of treatment sensitivity and prognostic factors in a Phase III, randomized, controlled study comparing the efficacy and safety of mFOLFOX6 + bevacizumab therapy vs. mFOLFOX6 + panitumumab therapy in patients with chemotherapy-naive wild-type RAS(KRAS/NRAS) unresectable advanced or recurrent colorectal cancer

Takeda Pharmaceutical Company Limited0 个研究点目标入组 757 人开始时间: 2015年3月6日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
入组人数
757

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
>= 20age old 至 <= 79age old(—)
性别
All

入选标准

  • Patients who are enrolled in the main study and personally provided written consent after adequately explained about the contents of the additional study

排除标准

  • Patients who are determined by the investigator or researchers to be not suitable for participating in the additional study

研究者

相似试验